Founded Date: 2014
Last Funding Type: Series B
Headquarters: Paris, Ile-de-France, France
Investors Number: 9
Technology: Neurological Disorders
Employee Number: 11-50
Industry: Gene Therapy
Estimated Revenue: $1M to $10M
Number Of Exists: Series B
Funding Status: Early Stage Venture
Investor Type: Company
Investment Stage: N/A
Total Funding: €27.1M